Association between complicated liver cirrhosis and the risk of hepatocellular carcinoma in Taiwan

Tsung-Hsing Hung1,2, Chih-Ming Liang3, Chien-Ning Hsu4,5, Wei-Chen Tai3,6, Kai-Lung Tsai7, Ming-Kun Ku8, Jiunn-Wei Wang9, Kuo-Lun Tseng9, Lan-Ting Yuan10, Seng-Howe Nguang11, Shih-Cheng Yang3, Cheng-Kun Wu3, Pin-I Hsu12, Deng-Chyang Wu9*, Seng-Kee Chuah3,6*

1 Division of Gastroenterology, Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan, 2 School of Medicine, Tzu Chi University, Hualien, Taiwan, 3 Division of Hepato-gastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 4 Department of Pharmacy, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 5 School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, 6 Chang Gung University, College of Medicine, Kaohsiung, Taiwan, 7 Division of Colon and Rectal Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, 8 Division of Gastroenterology; FooYin University Hospital, Pin-Tung, Taiwan, 9 Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital and Center for Stem Cell Research, Kaohsiung Medical University, Kaohsiung, Taiwan, 10 Divisions of Gastroenterology, Yuan General Hospital, Kaohsiung, Taiwan, 11 Division of Gastroenterology, Pin-Tung Christian Hospital, Pin-Tung, Taiwan, 12 Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Veterans General Hospital, National Yang-Ming University, Kaohsiung, Taiwan

* Chuahsk@seed.net.tw (SKC); dechwu@yahoo.com (DCW)

Abstract

Hepatic encephalopathy, ascites, and variceal bleeding are the three major complications of cirrhosis. It is well known that cirrhosis is the most important risk factor of hepatocellular carcinoma (HCC). However, little is known about whether the severity of liver cirrhosis has an effect on the incidence of HCC. This population-based cohort study aimed to explore the association between complicated cirrhosis and HCC, and identify the risk factors of HCC in patients with complicated cirrhosis. Data of the years 1997–2011 were extracted from the National Health Insurance Research Database of Taiwan. A total of 2568 patients with complicated cirrhosis without HCC at baseline were enrolled. After propensity score matching, another 2568 patients with non-complicated cirrhosis were included. Hazards Cox regression analysis by using a competing risk regression model to control for possible confounding factors was utilized to estimate the association of the complications of liver cirrhosis with the risk of HCC. We observed by using competing risk analysis that the adjusted hazard ratio (HR) for developing HCC during the follow-up period after the initial hospitalization was higher among the patients with baseline complicated cirrhosis than in those with uncomplicated cirrhosis (HR, 1.23; 95% confidence interval, CI, 1.10–1.37, p<0.001). Additionally, older patients (HR, 1.01; 95% CI, 1.01–1.02, p<0.001), males (HR, 0.84; 95% CI, 0.74–0.96, p = 0.009), and patients with alcohol-related cirrhosis (HR, 1.93; 95% CI, 1.65–2.26, p<0.001) had a statistically significant difference in the incidence of HCC. In conclusion,
complicated liver cirrhosis is associated with a higher risk of HCC in Taiwan compared with cirrhosis without complications.

Introduction

Hepatocellular carcinoma (HCC) represents 70%-85% of primary liver malignancies [1,2]. With abdominal sonography, we can screen for HCC and perform surveillance to detect and treat tumors in the early stages. It is well known that most cases of HCC are associated with cirrhosis regardless of the etiology [3–8]. The 5-year cumulative risk of developing HCC for patients with cirrhosis ranges between 5% and 30% [3, 4]. The mortality of patients with cirrhosis with cirrhosis-related complications is high and many of them die before they develop HCC [9–11]. However, it has not been reported whether the complications of cirrhosis are associated with the development of HCC. It is interesting and noteworthy to better understand the association between the two by using competing risk analysis model appropriately. It is well known that male patients have a higher risk of HCC than female patients do, and the risk of cirrhosis is also higher in male patients [12–15]. Since cirrhosis is the most important risk factor of HCC, it will be interesting to know the difference in the incidence of HCC between the sexes in patients with cirrhosis, especially in those with complications.

This population-based cohort study aimed to explore the association between complicated cirrhosis and HCC, and identify the risk factors of HCC in patients with complicated cirrhosis.

Materials and methods

Compliance with ethical requirements and database

This protocol was approved by the institutional review board and the Ethics Committee of Chang Gung Memorial Hospital and Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. The Ethics Committee waived the requirement for informed consents for this study, and the data were analyzed anonymously. The claims data for our study were collected from Taiwan’s National Health Insurance Research Database (NHIRD) for the years 1997–2011. A cohort dataset of one million randomly selected individuals was used, which was released by the National Health Research Institutes. The released dataset for this study did not include the private data of the patients or their health care providers. The details of the database have been described in previous studies [16–18]. Kaohsiung Medical Center is one of the sites of the Collaboration Center of Health Information Application, Ministry of Health and Welfare. The data analyst of our study was one of the staff members and she analyzed the health care data, which included the enrollment files and claims data.

Study sample

A schematic flowchart of the study design is shown in Fig 1. Data were extracted from the NHIRD using the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 571.5, or code 571.2 to screen for index hospitalization of patients with an initial diagnosis of liver cirrhosis who were discharged between January 1, 1997 and December 31, 2011 (n = 9435). All these patients were followed up until December 31, 2011. In this population-based cohort study, a total of 1690 patients with cirrhosis with baseline diagnosis of HCC (ICD-9-CM code 155.0) during or prior to the index hospitalization were excluded.
Subsequently, a total of 7745 patients with cirrhosis were recruited. They were then divided into two groups: the complicated liver cirrhosis and uncomplicated liver cirrhosis groups (n = 2568 and n = 5177, respectively). Complicated liver cirrhosis was defined as cirrhosis with cirrhosis-related complications. The complications of liver cirrhosis in our study were hepatic encephalopathy (HE) (ICD-9-CM code 572.2), variceal bleeding (VB) (ICD-9-CM code 456.0, 456.20, or 456.8), and ascites (ICD-9-CM code 789.5, or procedure code 54.91).

We performed one-to-one case-control match using propensity score matching (PSM) to avoid the interference of confounding factors. The factors for PSM were age, sex, year of enrollment, alcohol-related, diabetes mellitus, hypertension, and hyperlipidemia. After PSM, 2568 patients with uncomplicated cirrhosis were enrolled in this study as matched controls. Death was considered the competing risk when calculating the hazard ratios (HR) of HCC during the study period. The comorbidities included alcohol-related disorders (ICD-9-CM codes 291, 303.00–305.03, 571.0–571.3), hypertension (ICD-9-CM codes 401–405), hyperlipidemia (ICD-9-CM code 272), and diabetes mellitus (ICD-9-CM code 250).

Statistical analyses

The baseline characteristics were compared using Student t test and chi-square analyses for continuous and nominal variables, respectively. Hazards Cox regression by using competing risk regression model was used to control possible confounding factors. The values of $P < 0.05$ were considered statistically significant. The analyses were performed using the statistical software package SAS version 9.3 (SAS Institute Inc., Cary, NC, 2013).

Results

Table 1 shows the distribution of the demographic characteristics and comorbidities at baseline for the two groups of patients with cirrhosis with and without cirrhosis-related complications. Of the 2568 patients with complicated liver cirrhosis, the mean age was $57.1 \pm 15.4$ years and 1825 (71.0%) were males. Of the 2568 patients with uncomplicated liver cirrhosis, the mean age was $57.6 \pm 15.6$ years and 1784 (69.5%) were males. Seven-hundred and sixty six
patients (28.9%) in the complicated liver cirrhosis group and 743 (29.9%) in the uncomplicated group had alcohol-related cirrhosis. There were no significant differences between the two groups in the incidence of other comorbidities such as diabetes mellitus (27.1% vs. 25.4%, p = 0.173), hyperlipidemia (8.0% vs. 8.2%, p = 0.838), and hypertension (23.5% vs. 22.9%, p = 0.60). Table 2 demonstrates the outcomes in male and female patients. Among the 5136 patients with cirrhosis, 1269 patients developed HCC during the follow up period with male predominance (n = 863, 68.0%).

At the same time, 1810 patients died during the follow up period and were also male predominance (n = 1243, 68.7%).

### Table 1. Demographic characteristics of complicated and uncomplicated cirrhotic patients.

| Characteristics                  | Complicated cirrhotic patients (n = 2568) | Uncomplicated cirrhotic patients (n = 2568) | P value |
|----------------------------------|------------------------------------------|--------------------------------------------|---------|
| Male, n (%)                      | 1825 (71.1)                              | 1825 (71.1)                                | 0.211   |
| Age, years                       | 57.1± 15.4                               | 54.1± 15.6                                 | 0.206   |
| Comorbid conditions              |                                          |                                            |         |
| Acute myocardial infarction, n (%)| 24 (0.93)                                | 33 (1.29)                                  | 0.231   |
| Congestive heart failure, n (%)   | 208 (8.10)                               | 199 (7.75)                                 | 0.642   |
| Peripheral vascular disease      | 34 (1.32)                                | 48 (1.87)                                  | 0.119   |
| Connective tissue disorder       | 33 (1.29)                                | 30 (1.17)                                  | 0.704   |
| HIV                              | 3 (0.12)                                 | 6 (0.23)                                   | 0.317   |
| Alcohol-related, n (%)           | 766 (29.8)                               | 743 (28.9)                                 | 0.481   |
| DM, n (%)                        | 696 (27.1)                               | 653 (25.4)                                 | 0.173   |
| Hyperlipidemia, n (%)            | 206 (8.0)                                | 210 (8.2)                                  | 0.838   |
| Hypertension, n (%)              | 604 (23.5)                               | 588 (22.9)                                 | 0.597   |
| Year of enrollment               |                                          |                                            | 0.704   |
| 1997                             | 69 (2.69%)                               | 65 (2.53%)                                 |         |
| 1998                             | 67 (2.61%)                               | 69 (2.69%)                                 |         |
| 1999                             | 67 (2.61%)                               | 64 (2.49%)                                 |         |
| 2000                             | 62 (2.41%)                               | 76 (2.96%)                                 |         |
| 2001                             | 97 (3.78%)                               | 101 (3.93%)                                |         |
| 2002                             | 98 (3.82%)                               | 109 (4.24%)                                |         |
| 2003                             | 154 (6.00%)                              | 156 (6.07%)                                |         |
| 2004                             | 178 (6.93%)                              | 167 (6.50%)                                |         |
| 2005                             | 271 (10.55%)                             | 256 (9.97%)                                |         |
| 2006                             | 245 (9.54%)                              | 230 (8.96%)                                |         |
| 2007                             | 246 (9.58%)                              | 229 (8.92%)                                |         |
| 2008                             | 258 (10.05%)                             | 243 (9.46%)                                |         |
| 2009                             | 239 (9.31%)                              | 257 (10.01%)                               |         |
| 2010                             | 290 (11.29%)                             | 270 (10.51%)                               |         |
| 2011                             | 227 (8.84%)                              | 276 (10.75%)                               |         |

**Abbreviations:** DM, diabetes mellitus; HIV: human immunodeficiency virus

https://doi.org/10.1371/journal.pone.0181858.t001

### Table 2. Outcomes of cirrhotic patients with difference sex.

| Characteristics | Complicated cirrhotic patients (n = 2568) | Uncomplicated cirrhotic patients (n = 2568) |
|-----------------|------------------------------------------|--------------------------------------------|---------|
| Endpoint        |                                          |                                            |         |
| HCC*            | 470                                      | 208                                        | 28.0    |
| Male (n = 1825) |                                          | Female (n = 743)                           |         |
| Death**         | 719                                      | 317                                        | 42.7    |
| Male (n = 1810) |                                          | Female (n = 759)                           |         |

**Abbreviations:** HCC: hepatocellular carcinoma

* Among the 5136 cirrhotic patients, 1269 patients encountered the occurrence of the HCC during the follow up period with male predominance (n = 863, 68.0%).

**At the same time, 1810 patients died during the follow up period and were also male predominance (n = 1243, 68.7%).

https://doi.org/10.1371/journal.pone.0181858.t002
At the same time, 1810 patients died during the follow up period and the mortality was higher in men (n = 1243, 68.7%). The cumulative incidences of HCC in the complicated and non-complicated cirrhosis groups were 35.6% and 29.1% in ten years, respectively (P = 0.002).

In the complicated cirrhosis group, 40.3% (1036/2568) patients died before developing HCC, while 30.1% (774/2568) died before developing HCC in the non-complicated cirrhosis group. The percentages of patients who developed HCC before death in the complicated and non-complicated cirrhosis groups were 26.4% (678/2568) and 23.0% (591/2568), respectively.

After adjusting for gender, age, and medical comorbidities, patients with complicated cirrhosis had a higher risk of HCC than those with uncomplicated cirrhosis (HR, 1.23; 95% confidence interval, CI, 1.11–1.37, p < 0.001). Additionally, older patients (HR, 1.01; 95% CI, 1.01–1.02, p < 0.001), males (HR, 0.84; 95% CI, 0.74–0.96, p = 0.009), and patients with alcohol-related cirrhosis (HR, 1.93; 95% CI, 1.65–2.26, p < 0.001) had a statistical significant difference in the incidence of HCC (Table 3).

The cumulative incidences of HCC are presented in Fig 2. The cumulative incidence curves for HCC showed that the incidence was much higher in patients with complicated cirrhosis than in those with uncomplicated cirrhosis (p<0.001).

### Discussion

Although it is well known that cirrhosis is the most important risk factor of HCC [3–8], little is known about whether the severity of cirrhosis can affect the development of HCC in patients with cirrhosis. Certain studies have established the correlation between the degree of liver fibrosis and HCC [19, 20]. Cirrhotic patients with complications are in decompensated states. In this study, we evaluated the risk of developing HCC in different severities of liver cirrhosis. Liver cirrhosis with complications is reflective of the severity of liver disease, and is correlated with higher incidence of HCC.

Previous studies have showed that the annual incidence of HCC in patients with cirrhosis was about 3–5 percent per year, which was the same as that in the current study [21–23]. However, the mortality in patients with cirrhosis is high, especially in those with cirrhosis-related complications. Therefore, it may not be easy to estimate the actual risk of developing HCC in patients with cirrhosis because many of them die before they develop HCC. In clinical practice, physicians usually pay more attention to the cirrhosis-related complications in these patients due to the high mortality associated with them. Rationally, the presence of cirrhosis-related

---

### Table 3. Adjusted hazard ratios for the occurrence of hepatocellular carcinoma (HCC) during the follow-up period following first hospitalization by using competing risk analysis.

| Variable          | Hazard ratio | 95% confidence interval | P value |
|-------------------|--------------|-------------------------|---------|
| Age               | 1.01         | 1.01–1.02               | <0.001  |
| Male              | 0.84         | 0.74–0.96               | 0.001   |
| Alcohol-related   | 1.93         | 1.65–2.26               | <0.001  |
| Diabetes mellitus | 0.90         | 0.98–1.01               | 0.403   |
| Hypertension      | 1.16         | 1.00–1.35               | 0.046   |
| Hyperlipidemia    | 1.26         | 0.99–1.59               | 0.061   |
| With complications* | 1.23       | 1.10–1.37               | <0.001  |
| Year of enrollment| 0.99         | 0.98–1.01               | 0.403   |

* Abbreviations: HCC, hepatocellular carcinoma
  hepatic encephalopathy, esophageal variceal bleeding, or hepatic encephalopathy

https://doi.org/10.1371/journal.pone.0181858.t003
complications represents a more advance stage of the disease. Nevertheless, there are only a few studies on the association between cirrhosis-related complications and the risk of HCC. Furthermore, there may be many other confounding factors during the process of data analysis. In the current study, we performed PSM using one-to-one case-control matching to minimize bias. Finally, we included 2568 patients with uncomplicated cirrhosis as matched controls. Since death was considered as the competing risk when calculating the hazards ratio of HCC, a competing risk analysis model was used to assess the actual risk of HCC in these patients.

Among a total of 1269 cirrhosis patients with HCC, 863 (68.0%) were male, which is in accordance with the current literature. Previous reports suggest a male/female ratio in patients with HCC to be between 2:1 and 4:1 in almost all populations [14]. In this study, about 70% of patients with cirrhosis were also males. This can explain the male predominance in HCC. On the other hand, interestingly, the current study observed that the risk of HCC in female patients with cirrhosis is not lower than that in male patients with cirrhosis, after adjusting for other factors as shown in Table 3 (HR: 0.85; 95% CI 0.75–0.97). This may suggest that the male predominance in HCC may just be because of the higher incidence of liver cirrhosis in male patients. In Taiwan, the vaccination program against hepatitis B virus (HBV) infection was initiated in 1984, which has reduced the incidence of HCC in children and adolescents successfully [24]. Huang et al. later reported that the hazards ratio of developing HCC decreased with age in HBsAg-seropositive men but increased with age in anti-HCV-seropositive women [25]. Further studies are needed to explain these observations. These findings remind physicians to closely monitor the patients with cirrhosis for HCC, regardless of the gender.

Fig 2. Cumulative incidence curves for the hepatocellular carcinoma (HCC) in complicated and uncomplicated cirrhotic patients.
The adjusted hazard ratios for HCC during the follow-up period following the first hospitalization by using competing risk analysis showed that alcohol consumption is an important risk factor among these patients (HR, 1.93; 95% CI, 1.65–2.26, p < 0.001). This finding is in accordance with reports in the literature that alcohol consumption is an important risk factor for HCC, especially in patients with liver cirrhosis [26]. It is well established that the amount of alcohol consumption is proportionally correlated to the degree of liver injury and, hence, of developing cirrhosis and HCC [27]. Turati and colleagues reported that consumption of three or more drinks per day resulted in 16% higher risk of liver cancer and consumption of six or more drinks per day resulted in 22% higher risk [28].

This study has some limitations. First, we were unable to assess the severity of liver cirrhosis as measured by validated scoring systems such as MELD score or Child-Pugh score because we could not identify laboratory information from the dataset. The drugs used in these patients could not be identified, either. This is the major limitation of our study. Second, we could not distinguish between the etiologies of non-alcoholic liver cirrhosis in this study and some personal data such as body weight were not identifiable. However, the strength of our study is that we have demonstrated that patients with complicated cirrhosis had a higher risk of HCC, implying that the more advanced stages of liver disease carry higher risk of HCC. Further large-scale clinical studies are required to clarify the actual association of the severity of liver cirrhosis and HCC. Third, the surveillance procedures of HCC could not be identified in this study and the diagnosis of HCC is based on ICD-9 coding. Fourth, to increase the accuracy of diagnosis, we screened for hospitalized patients with an initial diagnosis of liver cirrhosis. However, the patients who are relatively “healthy” do not need admission. Indeed, the severity of cirrhosis in the patients in this study was greater than that in outpatients, and this may have led to selection bias. Otherwise, HCC was one of the reasons for admission and many patients with cirrhosis were admitted for the treatment of HCC. This could explain why there was such a high initial rate of HCC in this study.

In conclusion, complicated liver cirrhosis is associated with a higher risk of HCC in Taiwan compared to those without complications.

Supporting information
S1 Dataset. This file provides the data of the manuscript.
(XLS)

Acknowledgments
The authors thank Professor Yi-Hsin Yang and the Center for Medical Informatics and Statistics, Kaohsiung Medical University for their suggestions and help with data analysis. The authors would like to acknowledge Miss Ching-Yi Lin for her assistance in this study.

Author Contributions
Conceptualization: Tsung-Hsing Hung, Chien-Ning Hsu, Kuo-Lun Tseng, Lan-Ting Yuan, Seng-Howe Nguang, Cheng-Kun Wu, Seng-Kee Chuah.

Data curation: Chih-Ming Liang, Chien-Ning Hsu, Wei-Chen Tai, Kuo-Lun Tseng, Lan-Ting Yuan, Seng-Howe Nguang, Shih-Cheng Yang, Cheng-Kun Wu, Pin-I Hsu, Seng-Kee Chuah.

Formal analysis: Chih-Ming Liang, Chien-Ning Hsu, Wei-Chen Tai, Kuo-Lun Tseng, Lan-Ting Yuan, Shih-Cheng Yang, Seng-Kee Chuah.
Funding acquisition: Deng-Chyang Wu.

Investigation: Tsung-Hsing Hung, Chih-Ming Liang, Wei-Chen Tai, Pin-I Hsu, Seng-Kee Chuah.

Methodology: Tsung-Hsing Hung, Chih-Ming Liang, Wei-Chen Tai, Ming-Kun Ku, Pin-I Hsu, Seng-Kee Chuah.

Project administration: Chih-Ming Liang, Ming-Kun Ku, Pin-I Hsu.

Resources: Kai-Lung Tsai, Ming-Kun Ku, Jiunn-Wei Wang, Pin-I Hsu, Seng-Kee Chuah.

Software: Kai-Lung Tsai, Ming-Kun Ku, Jiunn-Wei Wang, Shih-Cheng Yang.

Supervision: Deng-Chyang Wu, Seng-Kee Chuah.

Validation: Jiunn-Wei Wang.

Visualization: Jiunn-Wei Wang, Shih-Cheng Yang.

Writing – original draft: Tsung-Hsing Hung.

Writing – review & editing: Deng-Chyang Wu, Seng-Kee Chuah.

References

1. Cabibbo G, Craxi A. (2010) Epidemiology, risk factors and surveillance of hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 14: 352–355. PMID: 20496547

2. Mittal S, El-Serag HB. (2013) Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 47 Suppl:S2–S6. https://doi.org/10.1097/MCG.0b013e3182872729 PMID: 23632345

3. Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, et al. (2016) Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 43: 621–630 https://doi.org/10.1111/apt.13505 PMID: 26784271

4. Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. (2015) Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 149: 1471–1482 https://doi.org/10.1053/j.gastro.2015.07.056 PMID: 26255044

5. Kim MN, Kim SU, Kim BK, Park JY, Kim DY, Ahn SH, et al. (2015) Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 61: 1851–1859 https://doi.org/10.1002/hep.27735 PMID: 25643638

6. Stickel F. Alcoholic cirrhosis and hepatocellular carcinoma. (2015) Adv Exp Med Biol. 815:113–130. https://doi.org/10.1007/978-3-319-09614-8_7 PMID: 25427904

7. El-Serag HB. (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 142: 1264–1273 https://doi.org/10.1053/j.gastro.2011.12.061 PMID: 22574342

8. Fattovich G1, Stroffolini T, Zagni I, Donato F. (2004) Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 127: S35–50. PMID: 15508101

9. Hung TH, Tsai CC, Hsieh YH, Tsai CC, Tseng CW, Tseng KC. (2016) The Effect of the First Spontaneous Bacterial Peritonitis Event on the Mortality of Cirrhotic Patients with Ascites: A Nationwide Population-Based Study in Taiwan. Gut Liver. 10: 803–807. https://doi.org/10.5009/gnl13468 PMID: 27563023

10. Hung TH, Lay CJ, Chang CM, Tsai JJ, Tsai CC, Tsai CC. (2013) The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy. Epidemiol Infect. 141: 2671–2678. https://doi.org/10.1017/S0950268813000186 PMID: 2343300

11. Hung TH, Tsai CC, Hsieh YH, Tsai CC, Tseng CW, Tsai JJ. (2012) Effect of renal impairment on mortality of patients with cirrhosis and spontaneous bacterial peritonitis. Clin Gastroenterol Hepatol. 10: 677–681. https://doi.org/10.1016/j.cgh.2012.02.026 PMID: 22391345

12. Shi L, Feng Y, Lin H, Ma R, Cai X. (2014) Role of estrogen in hepatocellular carcinoma: is inflammation the key? J Transl Med. 12: 93. https://doi.org/10.1186/1479-5876-12-93 PMID: 24708807

13. Kew MC. (2013) Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol. 12: 173–182. PMID: 23396727
14. Ruggieri A, Barbati C, Malorni W. (2010) Cellular and molecular mechanisms involved in hepatocellular carcinoma gender disparity. Int J Cancer. 127: 499–504. https://doi.org/10.1002/ijc.25298 PMID: 20201099

15. Kaira M, Mayes J, Assefa S, Kaul AK, Kaul R. (2008) Role of sex steroid receptors in pathobiology of hepatocellular carcinoma. World J Gastroenterol. 14: 5945–5961. https://doi.org/10.3748/wjg.14.5945 PMID: 18932272

16. Hung TH, Lay CJ, Tseng CW, Tsai CC, Tsai CC. (2016) The Effect of Renal Function Impairment on the Mortality of Cirrhotic Patients: A Nationwide Population-Based 3-Year Follow-up Study. PLoS One. 11: e0162987 https://doi.org/10.1371/journal.pone.0162987 PMID: 27631098

17. Liang CM, Hsu CN, Tai WC, Yang SC, Wu CK, Shih CW, et al. (2016) Risk factors influencing the outcome of peptic ulcer bleeding in chronic kidney disease after initial endoscopic hemostasis: A nationwide cohort study. Medicine (Baltimore). 95: e4795.

18. Wang JW, Hsu CN, Tai WC, Ku MK, Hung TH, Tseng KL, et al. (2016) The Association of Helicobacter pylori Eradication with the Occurrences of Chronic Kidney Diseases in Patients with Peptic Ulcer Diseases. PLoS One. 11: e0164824. https://doi.org/10.1371/journal.pone.0164824 PMID: 27764171

19. Kim JH, Kim JW, Seo JW, Choe WH, Kwon SY. Noninvasive Tests for Fibrosis Predict 5-Year Mortality and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B. J Clin Gastroenterol. 2016; 50:882–888. https://doi.org/10.1097/MCG.0000000000000574 PMID: 27322532

20. Akuta N, Kobayashi M, Suzuki F, Sezaki H, Fujiyama S, Kawamura Y, et al. Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals. Oncology. 2016; 91:341–347. Epub 2016 Oct 1. https://doi.org/10.1159/000450551 PMID: 27694754

21. Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. (2010) The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 51:1972–1978. https://doi.org/10.1002/hep.23527 PMID: 20209604

22. Serfaty L, Aumaitre H, Chazouilleres O, Bonnand AM, Rosmorduc O, Poupon RE, et al. (1998) Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 27: 1435–1440. https://doi.org/10.1002/hep.510270535 PMID: 9581703

23. Fattovich G, Giustina G, Schalm SW, Hadzijannis S, Sanchez-Tapias J, Almasio P, et al. (1995) Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology. 21: 77–82. PMID: 7806171

24. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM et al. (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccines: a 20-year follow up study. J Natl Cancer Inst. 2009; 101:1348–1355 https://doi.org/10.1093/jnci/djp288 PMID: 19799364

25. Huang YT, Jen CL, Yang HI, Lee MH, Su J, Lu SN et al. (2011) Lifetime risk and sex difference of hepatocellular carcinoma among patients with chronic hepatitis B and C. J Clin Oncol. 29: 3643–3650 https://doi.org/10.1200/JCO.2011.36.2335 PMID: 21899897

26. International Agency for Research on Cancer (IARC). (1998) Monographs on the evaluation of carcinogenic risks to humans. Alcohol Drinking. 44: 207–215.

27. Batey RG, Burns T, Benson RJ, Byth K. (1992) Alcohol consumption and the risk of cirrhosis. Med J Aust. 156: 413–416. PMID: 1545749

28. Turati F, Galeone C, Rota M, Pelucchi C, Negri E, Bagnardi V et al. (2014) Alcohol and liver cancer: a systematic review and meta-analysis of prospective studies. Ann Oncol. 25: 1526–1535. https://doi.org/10.1093/annonc/mdu020 PMID: 24631946